Clinical Trial Update: A Beta-only IL-2 ImmunoTherapY Study [Phase 1, Phase 2]

View source ↗

Summary

Medicennа Therapeutics is evaluating a beta-only IL-2 immunotherapy (MDNA11) in Phase 1/2 across multiple advanced solid tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Gastric Cancer
• Melanoma
• Merkel Cell Carcinoma
• Non-small Cell Lung Carcinoma
• Pancreatic Adenocarcinoma

Drugs mentioned

• MDNA11 (Interleukin-2 beta-selective agonist)

Snippet

Sponsor: Medicenna Therapeutics, Inc. | Conditions: Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING